Recently, Cothera Bioscience, the parent company of Percans Oncology, has made new progress in the Phase II clinical trial of MYC gene inhibitor PC-002 in China. Beijing Cancer Hospital is conducting a multicenter, open-label, exploratory dose-ranging phase II study of Sepantronium Bromide in patients with relapsed/refractory c-Myc rearranged high-grade B-cell lymphoma (HGBCL) (clinical trial approval number: 2022LP00392). The study has been approved by the Ethics Committee of Beijing Cancer Hospital. The clinical trial is open to public for patient recruitment. All patients with relapsed/refractory c-Myc rearranged HGBCL who meet the requirements after screening will have the opportunity to participate in the study.
This multi-center clinical trial will be conducted at medical centers in Beijing, Shanghai, Guangzhou, Tianjin, Wuhan and Zhengzhou.
PC-002, the core product of Cothera Bioscience, is a first-in-class small molecule drug targeting MYC-mutated tumors. With a unique mechanism of action (MOA), PC-002 selectively induces MYC protein degradation and cell apoptosis in MYC-dependent tumors. With more than 50% of human cancers showing increased expression, MYC is regarded as one of the most important yet “undruggable” cancer targets. Via its unique mechanism, PC-002 selectively kills tumor cells with MYC mutation and may potentially target multiple indications in cancers.